Infliximab administered with shortened infusion times in a specialized IBD infusion unit: A prospective cohort study

  • Van Assche G
  • Vermeire S
  • Noman M
 et al. 
  • 19


    Mendeley users who have this article in their library.
  • 12


    Citations of this article.


Background and aims: Biological therapy with anti TNF agents requires parenteral administration and in the case of infliximab this involves in hospital treatment. We aimed to prospectively assess the safety and tolerance of infliximab infusion in patients with IBD in a specialized unit adhering to strict standard operation procedures including switch to accelerated 1. h infusions. Methods: A prospective audit of a referral center IBD infusion unit was performed. We recorded infusion times and all adverse events including hypersensitivity reactions. Patients were also polled about the impact of the treatment on quality of life (QOL). Results: On 20 consecutive days 177 patients were treated with infliximab and all participated. Of those infliximab 117 received 1. h infusions and 4 (2.2%) had an immediate infusion reaction. Median time on unit was optimal for those with 1. h infusions [1:35. h (IQR: 1:25-1:50)] without an increased risk of infusion reactions. Prophylactic therapy significantly increased the time on unit [3:20. h (IQR: 2:50-3:45), p

Author-supplied keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Infliximab
  • Infusion reactions
  • Medical therapy
  • Ulcerative colitis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Gert Van Assche

  • Séverine Vermeire

  • Maja Noman

  • Christine Amant

  • Ellen Weyts

  • Anita Vleminckx

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free